Good
Partially Aligned
Patient Risk:
Moderate
Summary
The response aligns well with the CALDOLOR boxed warning and related cardiovascular (MI/stroke) and gastrointestinal (bleeding/ulceration/perforation) risk messaging, including the “lowest effective dose/shortest duration” concept. Several duration thresholds (e.g., ~3 days fever; ~7 days pain) and many population-specific “extra caution” statements are not supported by the provided label excerpts and are therefore treated as unsupported/over-specified.
Category Scores
Accurate Statements
Extended use of ibuprofen increases the risk of stomach bleeding and ulcers.
BOXED WARNING/5.2: NSAIDs including ibuprofen cause serious GI adverse events including bleeding and ulceration; risk can occur during use and may relate to duration.
Extended use of ibuprofen increases the risk of kidney problems.
Not supported by the provided label excerpts (boxed warning/5.1/5.2 excerpts supplied).
Extended use of ibuprofen increases the risk of higher blood pressure or fluid retention.
Not supported by the provided label excerpts.
Longer-duration ibuprofen, especially at higher doses or daily use, can increase the chance of stomach irritation, ulcers, and gastrointestinal bleeding.
5.1/5.2 and BOXED WARNING: NSAIDs including ibuprofen increase risk of serious GI adverse events such as bleeding and ulceration; guidance supports lowest effective dose/shortest duration.
Longer-duration ibuprofen, especially at higher doses or daily use, can increase the chance of kidney injury or worsening kidney function.
Not supported by the provided label excerpts.
Longer-duration ibuprofen, especially at higher doses or daily use, can increase cardiovascular risk in some people.
BOXED WARNING/5.1: increased risk of serious CV thrombotic events including MI and stroke; risk may increase with duration and is observed most consistently at higher doses.
Longer-duration ibuprofen, especially at higher doses or daily use, can increase the risk of blood pressure increases and fluid retention.
Not supported by the provided label excerpts.
Ibuprofen is intended for short-term use at the lowest effective dose for most people.
5.1: to minimize potential risk, use lowest effective dose for shortest duration possible.
Unsupported Statements
If ibuprofen is needed for more than a few days, medical advice should be obtained rather than continuing on your own.
Not supported by the provided excerpts (no duration threshold guidance in supplied label text).
Using ibuprofen for fever beyond about 3 days should prompt checking with a clinician.
No fever-specific duration threshold in the provided label excerpts.
Using ibuprofen for pain beyond about 7 days should trigger a medical review.
No pain-duration threshold in the provided label excerpts.
Extended use of ibuprofen increases the risk of kidney problems.
Kidney risk statements are not present in the provided BOXED WARNING/5.1/5.2 excerpts.
Extra caution and medical advice should be sought before longer ibuprofen use (or without medical supervision) in pregnant people, especially later in pregnancy.
Pregnancy-specific guidance is not present in the provided excerpts.
Extra caution and medical advice should be sought before longer ibuprofen use (or without medical supervision) in people with a history of stomach ulcers or GI bleeding.
While 5.2 notes prior history of peptic ulcer disease and/or GI bleeding increases risk, the specific directive formulation (“extra caution and medical advice should be sought”) and “longer use” linkage are not directly supported in the provided excerpt.
Extra caution and medical advice should be sought before longer ibuprofen use (or without medical supervision) in people with kidney disease.
Not supported by provided excerpts.
Extra caution and medical advice should be sought before longer ibuprofen use (or without medical supervision) in people with uncontrolled high blood pressure, heart failure, or significant heart disease.
Not supported by provided excerpts.
Extra caution and medical advice should be sought before longer ibuprofen use (or without medical supervision) in people who take blood thinners or other medicines that increase bleeding risk.
The provided excerpts do not mention anticoagulants/bleeding-risk medication interactions.
Extra caution and medical advice should be sought before longer ibuprofen use (or without medical supervision) in older people due to higher side-effect risk.
While 5.2 states elderly patients are at greater risk for serious GI events, the provided excerpts do not support this as an across-the-board directive for “longer ibuprofen use” or “older people due to higher side-effect risk” broadly.
Ibuprofen should be stopped and urgent medical care obtained if there are black or bloody stools, vomiting blood, or severe stomach pain.
GI symptom-triggered action instructions are not included in the provided excerpts.
Ibuprofen should be stopped and urgent medical care obtained if reduced urination, sudden swelling, or severe flank/back pain occur, as these may indicate kidney issues.
Kidney symptom-triggered actions are not present in the provided excerpts.
Ibuprofen should be stopped and emergency care sought if chest pain, trouble breathing, weakness on one side, or sudden severe headaches occur.
Specific emergency symptom lists are not present in the provided excerpts.
For longer use, a clinician can advise whether pain or symptoms need diagnosis and whether ibuprofen should be changed to a different medication or lower dose.
Not supported by provided excerpts.
For longer use, a clinician can advise switching to a topical NSAID if the problem is localized (such as joint pain).
Not supported by provided excerpts.
For longer use, a clinician can advise combining medication with non-drug treatments such as heat/ice, physical therapy, and an exercise plan.
Not supported by provided excerpts.
For longer use, a clinician can advise getting checked for causes of symptoms that are not just temporary inflammation.
Not supported by provided excerpts.
Ibuprofen may be taken regularly for chronic musculoskeletal conditions, but it should be done with a clinician’s guidance, especially if use is daily.
Not supported by the provided excerpts.
Clinicians often recommend using the lowest effective dose of ibuprofen for ongoing/chronic use.
The ‘lowest effective dose for shortest duration possible’ concept is supported, but the broader statement about chronic regular use is not supported by provided excerpts.
Clinicians may check for risk factors such as history of ulcers or bleeding, kidney disease, heart disease, older age.
Only some risk domains are partially supported by the provided GI warning excerpt (prior GI bleeding/ulcer and elderly); kidney/heart disease risk-factor checking is not supported by provided excerpts.
Clinicians may consider alternatives to ibuprofen such as topical NSAIDs, acetaminophen, or non-drug options depending on the situation.
Not supported by provided excerpts.
Extra caution and medical advice should be sought before longer ibuprofen use (or without medical supervision) in people with a history of stomach ulcers or GI bleeding.
Provided excerpt supports increased risk in such patients, but not the specific instruction language or 'without medical supervision/longer use' framing.
Contradictions
Important Omissions
Explicit CABG surgery contraindication and/or boxed-warning framing that CV thrombotic risk can occur early and may increase with duration.
Importance:
High
Boxed warning statement that GI serious adverse events can occur at any time during use, with or without warning symptoms (not just after prolonged use).
Importance:
Moderate
No mention that risk guidance includes using lowest effective dose for shortest duration possible (present generally, but not tied to ‘earliest possible’/‘may occur early’ boxed-warning wording).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response correctly reflects major boxed-warning risk domains (serious CV thrombotic events and serious GI bleeding/ulceration), but includes many additional duration thresholds and symptom- and population-specific cautions not supported by the provided label excerpts. This could mislead readers about when to seek care or what risks are label-supported for CALDOLOR.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many claims (specific day-count thresholds, kidney/BP/fluid retention risks, pregnancy/anticoagulant guidance, and symptom-triggered stop/emergency instructions) are not supported by the provided CALDOLOR label excerpts.
Suggested Improvement
Limit assertions to the provided boxed-warning/5.1/5.2-supported content: serious CV thrombotic events (MI/stroke), serious GI events (bleeding/ulceration/perforation, can occur at any time), and the risk-minimization approach of lowest effective dose and shortest duration possible; avoid unlabelled duration thresholds and symptom checklists unless supported by additional label sections.